Citations

Clear

753 citation(s) found for "Chase, C G".

PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Weiss, J., Chintakuntlawar, Ashish, Worden, Francis P., Mehra, Ranee , Kang, Hyunseok , Zinner, Ralph G., Arnold, Susanne M. , Bhateja, Priyanka, Harrington, Kevin, Gupta, Shilpi, Zhao, Yujie, Pham, Dahn C., Najeeb, Sidra, Kaur, Varinder, Sukari, Ammar, Giri, Anshu , Panella, Timothy J., Grewal, Jaspreet, Galligan, Barbara, Nadler, Eric, Grant, Cliona, Arteta-Bulos, Rafael, Schaaf, David, Price, Katharine A., Kang, Hyunseok , Weiss, Jared, Kaczmar, John M. , Zinner, Ralph , Harrington, Kevin J. , Kaur, Varinder , Sukari, Ammar , Panella, Timothy, Grewal, Jaspreet Singh , Galligan, Barbara Marie, Nadler, Eric , Noble, David J. , Schaaf, David

Mayo Clinic

JAMA Oncology | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaoncol.2026.3492 | PMID 42752531 Get It

Importance The incidence of human papillomavirus type 16 (HPV16–positive) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is rising. Approved therapies offer a durable response to a minority of patients. Objective To determine the efficacy and safety of a therapeutic HPV16-targeted immunotherapy, PDS0101, in combination with pembrolizumab in participants with HPV16-positive R/M HNSCC, with separate evaluation of immune checkpoint inhibitor (ICI)–naive and ICI-resistant cohorts. Design, Setting, and Participants VERSATILE-002 was a phase 2, open-label, multicenter nonrandomized clinical trial conducted at 26 oncology centers from March 29, 2021, to May 15, 2025, across the US, UK, and Ireland using the Simon 2-stage optimal design. Efficacy analyses were performed on modified intent-to-treat (mITT) population; safety analyses included all participants who received 1 or more doses. Eighty-eight participants with histologically confirmed R/M HPV16-positive HNSCC were enrolled, of whom 87 (98.9%) received treatment and composed the safety population. Seventy five (85.2%) were in the mITT population used for efficacy analyses, of whom 53 (70.7%) were ICI-naive with a programmed cell death ligand 1 combined positive score of 1 or greater and 22 (29.3%) were ICI-resistant. Exposures Pembrolizumab (200 mg, intravenously, every 3 weeks for up to 35 cycles) plus subcutaneous PDS0101 (5 scheduled doses per protocol). Main Outcomes and Measures The primary end point was objective response rate (ORR) per the Response Evaluation Criteria in Solid Tumors , version 1.1, by a masked independent central reviewer. Secondary end points included progression-free survival (PFS), median overall survival (mOS), and safety, with exploratory end points of duration of response, disease control rate, and response rates by programmed cell death ligand 1 status. Results Of the 75 patients in the mITT population, the mean (SD) age was 64.0 (8.3) years; 4 individuals (5%) were female and 71 (95%) were male; and 2 individuals (3%) were Asian, 1 (1%) was Black, 5 (7%) were Hispanic, and 71 (95%) were White. Among 53 ICI-naive participants in the mITT cohort, ORR by the central reviewer was 34.0%, median PFS was 5.3 months (95% CI, 2.10-9.00), and mOS was 39.3 months (95% CI, 23.90 to not evaluable). Among 22 ICI-resistant patients in the mITT cohort, no objective responses were observed and the primary end point (ORR by central reviewer) was not met, but mOS was 14.8 months (95% CI, 8.50-26.00). The treatment was well tolerated, with 13.8% experiencing grade 3 or higher treatment-related adverse events. Conclusions and Relevance The results of this nonrandomized clinical trial suggest that PDS0101 plus pembrolizumab showed antitumor activity in ICI-naive HPV16-positive R/M HNSCC, with favorable safety, response rates, and survival outcomes. The findings support further evaluation in a first-line setting. Trial Registration ClinicalTrials.gov Identifier: NCT04260126
The Association of Flavin Mononucleotide and Lactate During Normothermic Regional Perfusion with Post-Transplant Liver Outcomes: An Exploratory Study
Fischer, R , Cywes, Claire , Ong, Olivia , Muñoz, Nicolás , Din, Sardar, Ibeabuchi, Tobenna , Brown‐Soler, Isabela , Mahmud, Nadim , Cederquist, K., Smith, Georgeine, Benko, Stephanie , Wehrle, Chase J. , Sonnenberg, Elizabeth M. , Gazala, Samir Abu , Markmann, James F. , Olthoff, Kim M. , Shaked, Abraham , Vyas, Frederick, Sellers, Marty T. , Jonge, Jeroen de , Sun, Keyue , Schlegel, Andrea , Abt, Peter L. , Fischer, Raphaël M J , Levine, Matthew H , Abu-Gazala, Samir , Markmann, James F , Olthoff, Kim M , Shaked, Abraham , Sellers, Marty , de Jonge, Jeroen , Sun, Keyue , Schlegel, Andrea , Abt, Peter L , Ong, Olivia , Din, Sardar Wali , Vyas, Frederick

Mayo Clinic

Medicina | August 24, 2026 | Volume: 62 | Issue: 9 | Pages: 1622

10.3390/medicina62091622 | PMID 42796229 Get It

Background and Objectives: Normothermic regional perfusion (NRP) is an effective technique to improve recipient outcomes. However, no valid methods for determining liver viability exist. Identifying relevant biological markers with clinical correlation to liver viability and recipient clinical outcomes is imperative to improve decision-making. Materials and Methods: Fifty-four donors undergoing NRP and their recipients were included. FMN was measured at the start, 1 h, and end of NRP. Lactate was measured at the start, 30, 60, and 90 min of NRP. Primary outcomes were early allograft function using the early allograft dysfunction (EAD) criteria and the model for early allograft function (MEAF). Secondary outcomes included the association with donor warm ischemia time (DWIT), stratified by 30 min. Spearman’s rho assessed correlations. Results: Forty (74%) livers were transplanted, with 5 (12.5%) recipients developing EAD and the mean MEAF score was 3.13 (1.49). FMN at all time points was significantly greater in the EAD group compared to the non-EAD group and was significantly correlated with the MEAF score (Peak FMN: rho = 0.507, p = 0.001). FMN during perfusion did not differ between DWIT < and ≥30 min. Lactate levels were similar across all groups and did not discriminate for adverse allograft outcomes. However, lactate levels during perfusion were higher in the DWIT ≥ 30 min group. Conclusions: These findings suggest that during NRP, elevated FMN, but not lactate, is associated with early allograft function.
NCCN Guidelines® Insights: Survivorship, Version 3.2026
Peterson, L., McDonough, Allison L. , Ansbaugh, Shannon M., Heredia, Ella J. Ariza, Armenian, Saro, Baker, K. Scott, Cathcart-Rake, Elizabeth J., Cohen, Stuart H. , Fairman, Nathan, Feliciano, Josephine, Flores, Tessa , Gabel, Nicolette , Hill‐Kayser, Christine E. , Hock, Karen, Kline-Quiroz, Cristina, Lee, Nita K., Mooney, Kathi, Moryl, Natalie , Neuman, Heather, Overholser, Linda, Patel, Chirayu G. , Porpiglia, Andrea, Saidain, Ava, Schapira, Lidia , Smith, Sophia K., Tenner, Laura, Ah, Diane Von , Zee, Phyllis, Freedman-Cass, Deborah, McMillian, Nicole, Ariza‐Heredia, Ella , Armenian, Saro H. , Ballinger, Tarah Jean , Cathcart-Rake, Elizabeth , Day, Andrew T. , Evgeniou, Evgenios , Feliciano, Josephine , Friedman, Debra L. , Hock, Karen , Kline‐Quiroz, Cristina , Moore, Halle C. F. , Neuman, Heather B. , Overholser, Linda , Porpiglia, Andrea S., Rogers, Laura Q. , Yang, Eric H. , Freedman-Cass, Deborah A., McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 17, 2026 | Volume: 24 | Issue: 8 | Pages: No page available

10.6004/jnccn.2026.0039 | PMID 42607712 Get It

The NCCN Guidelines for Survivorship offer guidance for health care providers who care for survivors of adult-onset cancer. These guidelines include screening, evaluation, and treatment recommendations for common physical and psychosocial problems resulting from cancer and its treatment and provide a framework for care coordination. They also present guidance for helping cancer survivors to enhance their wellness and maintain a healthy lifestyle. This article summarizes the panel’s current recommendations and recent updates regarding anxiety, depression, distress, and trauma in cancer survivors.
Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
Stevenson, James, Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R., Chang, Joe Y., Desai, Aakash, Dilling, Thomas J. , Dowell, Jonathan, Durm, Gregory A. , Gettinger, S., Grotz, Travis E., Gubens, Matthew A., Lackner, Rudy P., Lanuti, Michael, Levy, Benjamin, Loo, Billy W., Maldonado, Fabien, Morgensztern, Daniel , Mullikin, Trey C., Ng, Thomas, Owen, Dawn , Owen, Dwight H., Patil, Tejas, Polanco, Patricio M., Riess, Jonathan, Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P., Tam, Alda, Yau, Edwin, Yun, Karen, Gregory, Kristina, Hang, Lisa, Desai, Aakash , Desai, Aakash P , Axtell, Andrea L. , Bauman, Jessica R. , Bharat, Ankit , Gettinger, Scott , Grotz, Travis E. , Gubens, Matthew A. , Juloori, Aditya , Levy, Benjamin , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Maldonado, Fabien , Mullikin, Trey C. , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane , Yau, Edwin , Yun, Karen M. , Gregory, Kristina M., Hang, Lisa E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 17, 2026 | Volume: 24 | Issue: 8 | Pages: No page available

10.6004/jnccn.2026.0038 | PMID 42607715 Get It

Mesothelioma is a rare cancer that originates from the mesothelial surfaces of certain sites within the body. Pleural mesothelioma is the most common type and represents approximately 85% of mesotheliomas. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for evaluation and treatment in patients with pleural mesothelioma. The NCCN Guidelines will continue to be updated annually based on available clinical evidence and panel consensus.
Cellular senescence is associated with age-related loss of liver zonation and hepatocyte function
Laux, L , Aristel, Alisha, Ali, Syed, Evensen, K. Garrett , Havas, Aaron , Miao, Zhen , Zhang, Jane, Peters, Samuel, Hu, Jiayi , Angelini, Luise, Klaers, Maggie, Brocksome, Jennie, Lewis, Adam , Paidimukkala, N., Brown, Mary E., Carver, Chase M., Albrecht, Jeffrey H. , Wehner, April , Adams, Peter, Aliferis, Constantin, Adeyi, Oyedele, Dong, Xiao, Wang, Jinhua, Zhang, Nancy, Adeyi, Oyedele , Adeyi, Oyedele , Lande, Kathryn , Li, Meiyi , Havas, Aaron , Zhang, Jane, Peters, Sam , Angelini, Luise, Brown, Mary E., Carver, Chase Matthew , Schafer, Marissa , Khosla, Sundeep , Wang, Jinhua , Robbins, Paul D. , Niedernhofer, Laura J. , Miao, Zhen , Khosla, Sundeep , Niedernhofer, Laura J

Mayo Clinic

No container title available | August 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.08.743614 | PMID 42845483 Get It

Abstract The liver is organized into tightly regulated zones with distinct metabolic functions but zonation erodes with age. Cellular senescence contributes to aging and liver diseases, however, its impact on aging biology is ill-defined. As part of The Cellular Senescence Network Consortium, we used multiple spatial transcriptomics approaches (GeoMx, Visium, CosMx) with snRNA-seq to profile senescence signatures, zonation markers, and metabolic pathways in livers from wild-type (WT) mice of multiple ages. We observed a loss of canonical zone signatures in aged mouse livers characterized by “expansion” of midlobular (zone 2) marker gene expression, accompanied by diminished expression of zone 3 marker genes by middle-age (18 months), indicative of loss of cell identity. Multiple analytic approaches identified distinct age-, zone- and sex-specific senescence signatures, which were significantly associated with zonation markers changes. This was recapitulated in Ercc1 mutant models of accelerated senescence, supporting a causal role of senescent cells in liver aging. A “no-zone” hepatocyte-like cluster expanded with age and with the strongest Senescence-Associated Secretory Phenotype (SASP) profile. Gene expression profiles from senescent hepatocytes implicate decreased WNT signaling and increased BMP as contributing to age-related loss of zonation. Together, these data elucidate the role of senescent cells in driving aging biology in non-diseased liver through disruption of cell:cell signaling and the loss of metabolic and cell identity gene expression necessary for hepatocyte function.
Addition of High-Dose Vitamin D 3 to Standard Treatment in Patients With Metastatic Colorectal Cancer
Ng, Kimmie, Zemla, Tyler, Jackson, Nadine, Kalyan, Aparna, Devoe, Craig, Shusterman, Michael , Vijayvergia, Namrata , Wu, Christina S., Cohen, Stacey A., Pulsipher, Sidney, Shergill, Ardaman, Watson, Yasmeem, Kleiber, Barbara , Lee, Myounghee, Kohn, Christine G. , Zuckerman, Dan, Hollis, Bruce W., O’Reilly, Eileen M., Meyerhardt, Jeffrey A., Pulsipher, Sydney , Ng, Kimmie , Ou, Fang‐Shu , Zemla, Tyler , Devoe, Craig , Cohen, Stacey A. , Thalappillil, Jennifer S. , Schwartz, Lawrence H. , Zuckerman, Dan, Hollis, Bruce W. , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A.

Mayo Clinic

JAMA | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.9350 | PMID 42545685 Get It

Importance In a phase 2 randomized clinical trial, high-dose vitamin D 3 added to standard treatment improved progression-free survival (PFS) compared with standard-dose vitamin D 3 in patients with metastatic colorectal cancer (mCRC). Objective To determine if high-dose vitamin D 3 added to standard chemotherapy improves outcomes in patients with previously untreated mCRC. Design, Setting, and Participants Double-blind phase 3 randomized clinical trial enrolling 455 patients with previously untreated mCRC, conducted in the US through the National Clinical Trials Network from October 2019 to December 2022 (database freeze: July 15, 2024). Interventions mFOLFOX6 (modified FOLFOX6 [5-fluorouracil, leucovorin, oxaliplatin]) or FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab every 2 weeks with either high-dose vitamin D 3 (8000 IU daily × 14 days as loading dose followed by 4000 IU daily) or standard-dose vitamin D 3 (400 IU daily) until disease progression, intolerable toxicity, or withdrawal of consent. Main Outcomes and Measures The primary end point was PFS assessed by the unstratified log-rank test. Secondary end points included objective response rate, overall survival, and toxicity. Prespecified subgroup analyses of PFS were performed according to known prognostic factors. Results Among 455 randomized patients (median age, 59 years; 181 [40%] female) with median follow-up 20 months, the median PFS for high-dose vitamin D 3 (n = 228) was 11.8 months (95% CI, 10.3-13.3) vs 10.3 months (95% CI, 9.4-12.2) for standard-dose vitamin D 3 (n = 227) (1-sided log-rank P = .25). There were no significant differences in objective response rate between high-dose and standard-dose vitamin D 3 (51% [95% CI, 44%-58%] vs 44% [95% CI, 37%-50%], respectively; P = .12), or in overall survival (median, 25.6 vs 27.0 months; 1-sided log-rank P = .66). There were no clinically meaningful differences in the most common grade 3 or greater adverse events between the high- and standard-dose groups, including neutropenia (n = 67 [32%] vs n = 62 [30%]) and hypertension (n = 42 [20%] vs n = 49 [23%]) or in incidence of vitamin D–associated toxicities. Conclusions and Relevance Among patients with previously untreated mCRC, addition of high-dose vitamin D 3 , vs standard-dose vitamin D 3 , to standard chemotherapy plus bevacizumab did not improve PFS. Trial Registration ClinicalTrials.gov Identifier: NCT04094688
Characteristics of Gender-Diverse Patients With Breast Cancer
Cortina, Chandler S., Brazauskas, Ruta , Flanagan, Meghan R., Dill, Ellen D., Joseph, Kathe-Ann P., Trifonov, Alexandr , Kim, Esther A. , Kantor, Olga, Barmettler, Gabi , Rosenberger, Laura H., Jordan, Sumanas W., Perez, Megan M. , Jimenez, Rachel B., Smart, Alicia , Walker, J C, Lautner, Meeghan A., Siegel, Emily L., Brabender, Danielle , Al-Hilli, Zahraa, Cassidy, Michael R., Weiss, Anna, McCaffrey, Rachel L., Lee, M Catherine, Kaoutzanis, Christodoulos, Nguyen, Khoa N., Son, Jennifer D., Williams, Austin D., Madrigrano, Andrea, McLaughlin, Sarah A., Stolley, Melinda, Cortina, Chandler S. , Flanagan, Meghan R. , Mukhtar, Rita A. , Kantor, Olga , Rezak, Kristen M. , Rosenberger, Laura H. , Jimenez, Rachel , Kopkash, Katherine A. , Hughes, Tasha M. , Walker, Jasmine C. , Lautner, Meeghan Ann, Siegel, Emily , Al‐Hilli, Zahraa , Cassidy, Michael Ryan , Weiss, Anna, McCaffrey, Rachel Louise , Kaoutzanis, Christodoulos , Son, Jennifer D. , Williams, Austin David , Petroll, Andrew E. , Stolley, Melinda R.

Mayo Clinic

JAMA Network Open | July 23, 2026 | Volume: 9 | Issue: 7 | Pages: e2624824

10.1001/jamanetworkopen.2026.24824 | PMID 42490110 Get It

Importance Limited granular data exist on breast cancer in transgender, nonbinary, and/or gender-diverse (TGD) individuals. Objective To describe patient demographic and tumor clinicopathological variables, clinically relevant risk factors, method of breast cancer detection, treatment characteristics, and locoregional outcomes and to estimate a 5-year breast cancer–specific survival (BCSS). Design, Setting, and Participants This cohort study obtained data on patients treated from 1990 to 2023 from 22 US academic medical centers using institutional databases, electronic medical records, and tumor registries. Included participants were TGD individuals 18 years or older with stage 0 to IV breast cancer. A comparative breast cancer cohort was selected from the 2016 to 2021 Surveillance, Epidemiology, and End Results Program (SEER) breast cancer dataset. Data were analyzed from January to October 2025. Exposure Breast cancer. Main Outcomes and Measures Estimated 5-year BCSS and locoregional recurrence rates. Wilcoxon rank sum and χ 2 tests were used to compare continuous and categorical variables. Kaplan-Meier analysis was used to estimate 5-year BCSS. Results A total of 112 TGD persons (median [IQR] age at diagnosis, 42.5 [36.5-51.0] years; 104 individuals [92.9%] were assigned female at birth) with breast cancer and 1 with bilateral disease were included in the analysis. Forty-three patients (38.4%) used gender-affirming hormone therapy before diagnosis. Among the entire cohort, 58 patients (51.8%) detected their own breast cancer, 68 (60.7%) had a familial breast cancer history, and 16 (14.3%) had a pathogenic germline variant. Tumors were predominantly hormone receptor positive (96 [85.7%]) and early stage (29 [25.7%] ductal carcinoma in situ [DCIS]; 51 [45.1%] stage I). The TGD cohort, compared with patients with breast cancer in the SEER dataset (N = 480 915), was younger (median [IQR] age, 42.5 [36.5-51.0] years vs 62.0 [52.0-72.0] years), had a higher proportion of persons assigned male at birth (8 [7.1%] vs 3522 [0.7%]), more often had progesterone receptor–positive disease (89 [79.5%] vs 335 491 [69.8%]), and presented with earlier-stage disease (eg, DCIS: 29 [25.9%] vs 79 604 [16.6%]). With a median (IQR) follow-up time for the TGD cohort of 38 (24-74) months, 5-year BCSS was favorable at 96.2% (95% CI, 85.3%-99.0%). Conclusions and Relevance This cohort study of TGD patients with breast cancer found that this population was young and often detected their own tumors via self-examination, suggesting opportunities to improve early detection through screening for individuals at elevated risk. Although short-term BCSS appeared favorable, prospective research is essential to define evidence-based guidelines and elucidate long-term outcomes.
PRANA: A Deep Learning Method for Adapting Polygenic Risk Scores to Diverse Ethnic Groups
Levi, Hagai, Wang, Qin, Bolla, Manjeet K. , Dennis, Joe, Andrulis, Irene L., Antonenkova, Natalia, Au, Chun Hang, Freeman, Laura E. Beane, Bermisheva, Marina, Bodelon, Clara, Bojesen, Stig E., Brenner, Hermann, Brock, Ian W., Brüning, Thomas, Byers, Helen, Camp, Nicola J., Castelao, Jose E., Choi, Ji-Yeob, Chung, Wendy K., Collaborators, NBCS, Colonna, Sarah, Couch, Fergus J., Daly, Mary B., Devilee, Peter, Dörk, Thilo, Eliassen, A. Heather, Eriksson, Mikael, Evans, D. Gareth, Fasching, Peter A., Faw, Kierstin, García-Closas, Montserrat, Haiman, Christopher A., Hamann, Ute, Hartman, Mikael, Hooning, Maartje J., Hoppe, Reiner , Howell, Sacha J., Investigators, ABCTB, Investigators, SGBCC, Ito, Hidemi, Iwasaki, Motoki, Jakubowska, Anna, Jernström, Helena, Joseph, Vijai, Kaaks, Rudolf, Kang, Daehee, Khusnutdinova, Elza K., Kiprijanovska, Sanja , Koutros, Stella, Kristensen, Vessela N., Kurian, Allison W., Kwong, Ava, Lambrechts, Diether, Larson, Nicole L. , Marchand, Loic Le, Li, Shuai, Li, Jingmei, Lophatananon, Artitaya, Mannermaa, Arto, Matsuo, Keitaro, Maxwell, Whitney, Muir, Kenneth, Nevelsteen, Ines, Obi, Nadia, O’Brien, Katie M., Ofit, Kenneth, Ottewell, Penelope D., Patel, Alpa V., Plaseska-Karanfilska, Dijana, Prajzendanc, Karolina , Ramachandran, Dhanya, Rashid, Muhammad U., Saloustros, Emmanouil, Sandler, Dale P., Schöttker, Ben, Simard, Jacques, Southey, Melissa C., Stone, Jennifer, Teras, Lauren R., Truong, Thérèse, Weinberg, Clarice R., Yamaji, Taiki , Zheng, Wei, Easton, Douglas F., Elkon, Ran , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W. , Li, Shuai , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W , Li, Shuai , Levi, Hagai , Au, Chun , Augustinsson, Annelie , Freeman, Laura E. Beane , Behrens, Sabine , Bermisheva, Marina , Bodelón, Clara , Bogdanova, Natalia , Brenner, Hermann , Brock, Ian W., Brüning, Thomas , Byers, Helen, Camp, Nicola J. , Castelao, Jose E. , Choi, Ji-Yeob , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Czene, Kamila , Daly, Mary B., Devilee, Peter , Dörk, Thilo, Evans, D. Gareth , Fasching, Peter A., Faw, Kierstin, Gago-Domínguez, Manuela , García‐Closas, Montserrat , Haiman, Christopher A. , Hartman, Mikael , Ho, Vikki , Ho, Peh Joo , Hooning, Maartje J. , Investigators, S On Behalf Of The Chlovis Study, Iwasaki, Motoki , Jakubowska, Anna, Jernström, Helena , Joseph, Vijai, Kaaks, Rudolf , Хуснутдинова, Э. К. , Koutros, Stella , Kristensen, Vessela N., Kwong, Ava , Marchand, Loı̈c Le , Li, Jingmei, Lophatananon, Artitaya , Mannermaa, Arto , Nevelsteen, Ines , Obi, Nadia , O’Brien, Katie M. , Ottewell, Penelope Dawn , Peterlongo, Paolo , Plaseska‐Karanfilska, Dijana , Radice, Paolo , Ramachandran, Dhanya , Romero, Atocha , Saloustros, Emmanouil , Sandler, Dale P. , Schöttker, Ben , Simard, Jacques , Southey, Melissa C. , Sugier, Pierre‐Emmanuel , Taylor, Jack A. , Teras, Lauren R. , Truong, Thérèse , Weinberg, Clarice R. , Yadav, Siddhartha , Dunning, Alison M. , Mavaddat, Nasim , Easton, Douglas F. , Michailidou, Kyriaki , Shamir, Ron

Mayo Clinic

No container title available | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.12.26357860 | PMID 42523604 Get It

Abstract Polygenic risk scores (PRSs), which quantify inherited susceptibility to complex traits and diseases, have emerged as valuable tools for risk stratification and precision medicine. Despite their promise, PRS developed on European cohorts often demonstrate substantially reduced predictive accuracy in non-European populations, due to differences in genetic architecture. The disproportionate representation of European ancestry cohorts in genome-wide association studies (GWAS) leads to inequitable deployment of PRS technologies across diverse populations. Here, we introduce PRANA (Polygenic Risk Adaptation via Neural-network Architecture), a deep learning framework that adapts an existing PRS developed on one population to other ancestries. Unlike methods that require large-scale GWAS in the target population, PRANA leverages pre-trained PRS models derived from European cohorts and adapts them using modestly sized cohorts from the target population. We evaluated PRANA on seven complex traits in South Asian, East Asian and Ashkenazi Jewish populations, as well as in selected smaller East Asian subpopulations where the scarcity of training data poses a particular challenge. PRANA mostly improved predictive performance of the baseline PRS models by 5%-20% in terms of effect size (β) and Nagelkerke’s R², and, in most cases, outperformed existing cross-ancestry multi-PRS approaches. These results highlight PRANA as a scalable and practical strategy to reduce disparities in genomic risk prediction and advance the equitable application of PRS in diverse populations.
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026
Gerds, Aaron T., Gotlib, J, Abdelmessieh, Peter, Ali, Haris, Castells, Mariana, Chernak, Brian , Espinoza-Gutarra, Manuel R., Revell, Rebecca, Green, Steven, Gundabolu, Krishna , Hexner, Elizabeth, Jamieson, Catriona H., Khan, Irum, Kuykendall, Andrew T., McMahon, Brandon, Mohan, Sanjay R., Nadiminti, Kalyan V., Oh, Stephen, Palmer, Jeanne, Patel, Ami B. , Patel, Anand A., Rein, Lindsay, Salit, Rachel, Sehl, Mary, Wadleigh, Martha, Wall, Sarah A., Bergman, Mary Anne, Hochstetler, Cindy, Patel, Anand , Patel, Anand , Gerds, Aaron T. , Gotlib, Jason , Ali, Haris , Espinoza‐Gutarra, Manuel , Green, S, Hexner, Elizabeth O. , Jain, Tania , Khan, Irum , Kuykendall, Andrew , Madanat, Yazan F. , Masárová, Lucia , Mohan, Sanjay R., Nadiminti, Kalyan, Palmer, Jeanne , Podoltsev, Nikolai , Salit, Rachel B. , Sehl, Mary E. , Talpaz, Moshe , Wadleigh, Martha , Wall, Sarah

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 9, 2026 | Volume: 24 | Issue: 7 | Pages: No page available

10.6004/jnccn.2026.0034 | PMID 42425157 Get It

The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are a group of heterogenous hematologic malignancies characterized by the proliferation of blood cells and consist of myelofibrosis, polycythemia vera, and essential thrombocythemia. The NCCN Guidelines for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the aim of providing recommendations for the comprehensive care of adults with these diseases. The panel of experts convenes at least once a year to discuss requested changes to the Guidelines and to evaluate emerging data. These Guideline Insights focus on some of the recent updates for myelofibrosis.